Merlin L. Robb
A5076820552- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- Immune Cell Function and Interaction
- HIV/AIDS drug development and treatment
- T-cell and B-cell Immunology
- vaccines and immunoinformatics approaches
- HIV, Drug Use, Sexual Risk
- HIV-related health complications and treatments
- Herpesvirus Infections and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Hepatitis C virus research
- Virology and Viral Diseases
- Hepatitis B Virus Studies
- Immunotherapy and Immune Responses
- Adolescent Sexual and Reproductive Health
- Cytomegalovirus and herpesvirus research
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- Mosquito-borne diseases and control
- Viral Infections and Outbreaks Research
- Sex work and related issues
- Viral Infections and Vectors
- Virus-based gene therapy research
- COVID-19 Clinical Research Studies
- Blood groups and transfusion
Henry M. Jackson Foundation
2016-2025
Walter Reed Army Institute of Research
2016-2025
Duke University
2024
Purdue University West Lafayette
2024
University of Maryland, Baltimore
2019-2023
University of California, Los Angeles
2022
Jackson Foundation
2012-2021
Johns Hopkins University
1999-2021
Armed Forces Research Institute of Medical Science
1995-2021
Biomedical Advanced Research and Development Authority
2021
The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control.In community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections recombinant canarypox vector (ALVAC-HIV [vCP1521]) plus two booster glycoprotein 120 subunit (AIDSVAX B/E). placebo were administered 16,402 healthy men women between ages 18 30 years in Rayong Chon Buri provinces Thailand....
BackgroundThe Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in prefusion-stabilized conformation.MethodsIn an international, randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned adult participants 1:1 ratio to receive single dose of (5×1010 viral particles) or placebo. The primary end points were efficacy against moderate...
In the RV144 trial, estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed case–control analysis to identify antibody and cellular immune correlates infection risk.
ABSTRACT The role of antibody in protection against human immunodeficiency virus (HIV-1) has been difficult to study animal models because most primary HIV-1 strains do not infect nonhuman primates. Using a chimeric simian/human (SHIV) based on the envelope isolate (HIV-89.6), we performed passive-transfer experiments rhesus macaques anti-envelope antibodies protection. Based prior vitro data showing neutralization synergy by combinations, evaluated HIV immune globulin (HIVIG), and...
BackgroundThe safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection United States, Chile, Peru has not been known.MethodsIn this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated safety, efficacy, immunogenicity two doses as compared with placebo preventing onset symptomatic disease 2019 (Covid-19) 15 days or more...
A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in community-based population Thailand (RV144 trial). No was observed Thai injection drug users who received AIDSVAX B/E alone (Vax003 We compared the neutralizing antibody response these 2 trials.
Acute human immunodeficiency virus type 1 (HIV-1) infection is a major contributor to transmission of HIV-1. An understanding acute HIV-1 may be important in the development treatment strategies eradicate or achieve functional cure.
Serious non-AIDS events cause substantial disease and death despite human immunodeficiency virus (HIV) suppression with antiretroviral therapy (ART). Biomarkers of inflammation, coagulation cascade activation, fibrosis predict these end-organ events. We aimed to determine whether ART initiation during acute HIV infection would attenuate changes in biomarker levels. Plasma samples were obtained from participants starting or chronic HIV-uninfected Bangkok, Thailand. inflammation (C-reactive...
Mucosal Th17 cells play an important role in maintaining gut epithelium integrity and thus prevent microbial translocation. Chronic HIV infection is characterized by mucosal cell depletion, translocation subsequent immune-activation, which remain elevated despite antiretroviral therapy (ART) correlating with increased mortality. However, when depletion occurs following unknown. We analyzed 42 acute (AHI) subjects (Fiebig (F) stage I-V) a median duration of 16 days the short-term impact early...
Neutralizing and non-neutralizing antibodies to linear epitopes on HIV-1 envelope glycoproteins have potential mediate antiviral effector functions that could be beneficial vaccine-induced protection. Here, plasma IgG responses were assessed in three gp120 vaccine efficacy trials (RV144, Vax003, Vax004) HIV-1-infected individuals by using arrays of overlapping peptides spanning the entire consensus gp160 all major genetic subtypes circulating recombinant forms (CRFs) virus. In RV144, where...
HIV DNA is a marker of persistence that predicts progression and remission, but its kinetics in early acute infection (AHI) poorly understood. We longitudinally measured the frequency peripheral blood mononuclear cells harboring total integrated 19 untreated 71 treated AHI participants, for whom 50 were earliest Fiebig I/II (HIV IgM-) stage, ≤2weeks from infection. Without antiretroviral therapy (ART), peaked at 2weeks after enrollment, reaching set-point later with little change thereafter....
The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis.